azurin-derived cell-penetrating peptide p28
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Teratoid Tumor, Atypical
Conditions
Teratoid Tumor, Atypical, Choroid Plexus Neoplasms, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Brainstem Tumors, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Medulloblastoma, Neuroectodermal Tumor, Primitive
Trial Timeline
Aug 1, 2013 → Apr 1, 2015
NCT ID
NCT01975116About azurin-derived cell-penetrating peptide p28
azurin-derived cell-penetrating peptide p28 is a phase 1 stage product being developed by Brain Biotech for Teratoid Tumor, Atypical. The current trial status is completed. This product is registered under clinical trial identifier NCT01975116. Target conditions include Teratoid Tumor, Atypical, Choroid Plexus Neoplasms, Anaplastic Astrocytoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01975116 | Phase 1 | Completed |
Competing Products
2 competing products in Teratoid Tumor, Atypical
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tazemetostat + Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 1/2 | 40 |
| Gemcitabine + Paxalisib | Pacific Biosciences | Phase 2 | 44 |